Loading organizations...
Vi Labs has raised $36.0M across 2 funding rounds.
Key people at Vi Labs.
Vi Labs was founded in 2016 by Penny Pritzker (Founder).
Vi Labs has raised $36.0M in total across 2 funding rounds.
Vi Labs develops an enterprise AI platform specifically designed for the health sector, providing productized artificial intelligence solutions. This platform enables health organizations to effectively utilize data science capabilities, aiming to optimize both member health outcomes and financial returns across their operations. The company focuses on delivering measurable patient and operational return on investment through its advanced AI technology.
The company was co-founded by Omri Yoffe, who also serves as its Chief Executive Officer. Yoffe established Vi Labs with the insight that powerful data science and AI could be systematically applied within the health industry to drive significant improvements. This approach allows health enterprises to leverage sophisticated analytical tools without needing to build them from scratch, translating complex data into actionable strategies.
Vi Labs serves a broad range of health organizations, from large enterprises to digital health companies, by providing the intelligence needed to enhance their services. Its overarching mission is to empower these entities to maximize the health outcomes for their members while simultaneously achieving robust financial results. The company envisions a future where AI is central to improving health management and operational efficiency on a global scale.
Key people at Vi Labs.
Vi Labs was founded in 2016 by Penny Pritzker (Founder).
Vi Labs has raised $36.0M in total across 2 funding rounds.
Vi Labs's investors include ENIAC Ventures, Journey Ventures, Menlo Ventures, Square Peg Capital, Team8, Ben Barokas, Ben Lilienthal, Eytan Elbaz, Liat Aaronson, Yuval Shahar.
Vi Labs is an AI-focused technology company that builds an enterprise SaaS platform to help health organizations maximize member health outcomes and financial returns.[2][3][4] Its core products—VI Acquire, VI Engage, and VI Transform—address the full member lifecycle, from acquisition and engagement to operational efficiency, using AI for patient engagement, retention, and ROI optimization in healthcare, wellness, and pharma sectors.[1][3][4] The platform delivers up to 4X ROI, supports healthier lifestyles for patients, accelerates clinical trials by 76%, and reduces hospital costs by up to 50%, serving enterprises with anonymized data and strict privacy protocols.[2][4]
Founded in 2011 and headquartered in New York (with operations in Brooklyn, Los Angeles, Boston, and Tel Aviv), Vi Labs targets health enterprises, powering dynamic member experiences and operational transformations.[1][5] It solves critical signal detection in noisy healthcare data, akin to aerospace systems failures, through productized AI that enhances enrollment (up to 87% improvement), utilization, and drug development in oncology, epilepsy, and diabetes.[2][4]
Vi Labs originated from a tragic aerospace inspiration: a silent systems failure that killed an Air Force pilot friend, highlighting buried critical signals—a persistent issue in healthcare.[2] Founded in 2011 in New York, the company evolved from health and fitness SaaS (like Vi Engage for member retention) into a specialized AI provider for global health enterprises.[1][3] It expanded its product suite to include VI Acquire for media optimization, VI Engage for lifetime value growth, and VI Transform using generative AI for operations, while building subsidiaries in Los Angeles, Boston, and Tel Aviv to democratize personal wellness via white-label solutions.[3][5]
Early focus on cloud-based tools for health experts grew into an end-to-end AI platform, with pivotal traction in enterprise ROI delivery and recent leadership moves, such as CTO Vlad Iliushin joining AMTSO's board in 2022 to broaden cybersecurity testing influence.[1]
Vi Labs rides the AI-in-healthcare wave, where generative AI and data analytics address operational inefficiencies and personalized care amid rising healthcare costs and data overload.[2][3][4] Timing aligns with 2024-2025 AI reshaping reports on pharma, wellness, and hospitals, accelerating therapies and member engagement when post-pandemic demands amplify needs for retention and ROI.[4] Market forces like exploding health data volumes and regulatory pushes for privacy favor its anonymized, specialized platform, influencing the ecosystem by enabling 4X ROI at scale and faster drug development, thus bridging aerospace-inspired precision to wellness democratization.[1][2][5]
Vi Labs is poised to expand its enterprise AI orchestration amid surging demand for AI-driven health efficiencies, potentially dominating member lifecycle optimization as generative AI matures.[3][4] Trends like accelerated clinical trials, cost reductions, and personalized wellness will shape its path, with 2025 reports signaling deeper pharma and hospital integrations.[4] Its influence may evolve into a standard-setter for secure, high-ROI health AI, scaling from current impacts to broader ecosystem transformations—echoing its origin in turning signal-from-noise failures into precise, life-saving actions.[2]
Vi Labs has raised $36.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in January 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2018 | $20M Series A | — | Eniac Ventures, Journey Ventures, Menlo Ventures, Square PEG Capital, Team8, BEN Barokas, BEN Lilienthal, Eytan Elbaz, Liat Aaronson, Yuval Shahar | Announced |
| Mar 1, 2016 | $16M Seed | — | Eniac Ventures, Journey Ventures, Menlo Ventures, Square PEG Capital, Team8, BEN Barokas, BEN Lilienthal, Eytan Elbaz, Liat Aaronson, Yuval Shahar | Announced |